A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration. OTX-TKI-2023-AMD-303
Research Grant
Awarded By
Ocular Therapeutix Inc
Start Date
July 1, 2024
End Date
April 30, 2027
Awarded By
Ocular Therapeutix Inc
Start Date
July 1, 2024
End Date
April 30, 2027